Respiratorius AB (publ) (XSAT:RESP)

Sweden flag Sweden · Delayed Price · Currency is SEK
3.700
-0.020 (-0.54%)
At close: Aug 15, 2025
-0.54%
Market Cap18.86M
Revenue (ttm)30.00K
Net Income (ttm)-7.81M
Shares Out5.10M
EPS (ttm)-1.53
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume9,511
Average Volume15,585
Open3.800
Previous Close3.720
Day's Range3.620 - 3.800
52-Week Range3.560 - 10.500
Beta1.92
RSI21.92
Earnings DateAug 12, 2025

About Respiratorius AB

Respiratorius AB (publ), a research company, develops drug candidates for the treatment of cancer, chronic obstructive pulmonary disease (COPD), and asthma. The company’s products under development include VAL001, which has completed Phase III clinical trials for the treatment of diffuse large B-cell lymphoma; and VAL001, a product candidate that is in preclinical phase for the treatment of relapsing diffuse large B-cell lymphoma. Respiratorius AB (publ) was incorporated in 1998 and is based in Lund, Sweden. [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1998
Employees 1
Stock Exchange Spotlight Stock Market
Ticker Symbol RESP
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.